Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.54 |
| ▸ | MMP3 | P08254 | 4/20 | 0.54 |
| ▸ | MMP7 | P09237 | 3/20 | 0.54 |
| ▸ | MMP13 | P45452 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8207295 | 0.81 | MMP1 (0.61) | MMP1MMP3MMP7MMP13NPC1 | |
| SCHEMBL6977510 | 0.79 | MMP1 (0.63) | MMP1MMP3MMP7MMP13NPC1 | |
| SCHEMBL13037004 | 0.79 | PSEN1 (0.71) | MMP1MMP3MMP7MMP13NPC1 | |
| SCHEMBL3598308 | 0.79 | NAMPT (0.40) | TSHR | |
| SCHEMBL12162069 | 0.78 | NPC1 (0.60) | MMP1MMP3MMP7MMP13NPC1 | |
| SCHEMBL4133018 | 0.78 | MMP1 (0.56) | MMP1MMP3MMP7MMP13NPC1 | |
| SCHEMBL8206915 | 0.78 | MMP1 (0.58) | MMP1MMP3MMP7MMP13NPC1 | |
| SCHEMBL8207218 | 0.77 | MMP1 (0.57) | MMP1MMP3MMP7MMP13NPC1 | |
| SCHEMBL8207220 | 0.77 | MMP1 (0.57) | MMP1MMP3MMP7MMP13NPC1 | |
| SCHEMBL8207216 | 0.77 | MMP1 (0.57) | MMP1MMP3MMP7MMP13NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | claimed |
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PKD2, QPCT, CCNT2 | MMP1 4730/4885MMP3 4182/4885MMP7 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.